Abstract
Over a span of two decades, it has become increasingly clear that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of retinal diseases including age-related macular degeneration (AMD) and diabetic retinopathy (DR). Based on these observations, anti-VEGF therapies are being developed and approved for clinical use in the treatment of neovascular eye diseases. Hypoxia-inducible factors (HIFs) are transcriptional factors that are stabilized and activated under hypoxic conditions and induce expression of gene products, including VEGF, that are required for cell survival under hypoxia. Here we discuss recent findings from our lab and others that define roles of the HIF-VEGF axis in the retina.
| Original language | English |
|---|---|
| Pages (from-to) | 275-281 |
| Number of pages | 7 |
| Journal | Advances in experimental medicine and biology |
| Volume | 801 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
| Externally published | Yes |
Keywords
- Age-related macular degeneration
- Hypoxia-inducible factors
- Retinal pigment epithelium
- Vascular endothelial growth factor
- Von Hippel-Lindau tumor suppressor
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Fingerprint Dive into the research topics of 'Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina'. Together they form a unique fingerprint.
Cite this
Kurihara, T., Westenskow, P. D., & Friedlander, M. (2014). Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina. Advances in experimental medicine and biology, 801, 275-281. https://doi.org/10.1007/978-1-4614-3209-8_35